GLP-1 receptor agonists × glycemic control

TrialJAMA2017

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Melanie Davies et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 1,106 people · 2017

No range given

Reported lower glycemic control, no range given

−1.60percentage points

As reported

difference −1.6 %, no interval

One number in the abstract

the abstract, start to end

oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5 mg, <.001 for

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−1.6
GLP-1 receptor agonistsGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

203 papers cite itlatest 60 shown

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 29049653